Howard J Eisen
Affiliation: Temple University
- Immunosuppression on the horizonHoward J Eisen
Drexel University College of Medicine, Philadelphia, PA 19102, USA
Heart Fail Clin 3:43-9. 2007..Finally, costimulatory pathway inhibitors and other new immunosuppressive agents offer hope that all these goals can be accomplished with very low long-term maintenance immunosuppression...
- Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipientsHoward J Eisen
Section of Cardiology, Temple University, Philadelphia, PA 19140, USA
N Engl J Med 349:847-58. 2003..We conducted a randomized, double-blind, clinical trial comparing everolimus with azathioprine in recipients of a first heart transplant...
- Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipientsHoward J Eisen
Division of Cardiology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102 1192, USA
J Heart Lung Transplant 24:517-25. 2005..This study reports the 36-month results of a randomized, double-blind, active-controlled trial of mycophenolate mofetil (MMF) vs azathioprine (AZA) in heart transplant patients...
- Effect of older donor age on risk for mortality after heart transplantationDipin Gupta
Division of Cardiac and Thoracic Surgery, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA
Ann Thorac Surg 78:890-9. 2004..Our goal was to determine if older donor age is associated with an increased risk of mortality and specifically if the use of donor hearts at least 50 years of age reduces survival...
- Early growth responsive gene (Egr)-1 expression correlates with cardiac allograft rejectionMichael V Autieri
Department of Physiology, Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA
Transplantation 78:107-11. 2004..The goal of this work is to determine whether Egr-1 expression could be used as a surrogate marker of cardiac allograft rejection...
- Raman spectroscopy detects cardiac allograft rejection with molecular specificityYoon Gi Chung
Drexel University, Philadelphia, Pennsylvania 19104, USA
Clin Transl Sci 2:206-10. 2009....
- Expression of the FAST-1 transcription factor in coronary artery transplant vasculopathy and activated vascular smooth muscle cellsSheri F Kelemen
Department of Cardiology, Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA
J Heart Lung Transplant 24:246-50. 2005..Identification of genes expressed in activated VSMCs may provide clues to the pathogenesis and progression of cardiac allograft vasculopathy (CAV)...
- Cardiac transplantation across a positive prospective lymphocyte cross-match in sensitized recipientsStephen H Leech
Departments of Pathology and Laboratory Medicine, Temple University Hospital and School of Medicine, Philadelphia, PA, USA
Clin Transplant 17:17-26. 2003..The reason for undertaking the current study was to test the hypothesis that the constraints which a positive LCM result impose in preventing renal transplantation may not apply to orthotopic heart transplantation (OHT)...
- Factors affecting survival after heart transplantation: comparison of pre- and post-1999 listing protocolsAlfred A Bove
Section of Cardiology, Temple University School of Medicine, Philadelphia, Pennsylvania, USA
J Heart Lung Transplant 25:42-7. 2006..Because the selection process was modified in favor of seriously ill patients, it was not clear whether this change would affect survival or other aspects of transplant management...
- Serum 25-hydroxyvitamin D concentration and mortality from heart failure and cardiovascular disease, and premature mortality from all-cause in United States adultsLongjian Liu
Department of Epidemiology and Biostatistics, Drexel University School of Public Health, Philadelphia, PA, USA
Am J Cardiol 110:834-9. 2012..001, test for trend). In conclusion, adults with inadequate serum 25(OH)D levels have significantly higher risk of death from HF and all CVDs and all-cause premature death...
- Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathyMichael V Autieri
Department of Physiology, Cardiovascular Research Group, Temple University School of Medicine, Philadelphia, PA 19140, USA
Circulation 106:2218-23. 2002....
- Clinical utility of intravascular ultrasound in the assessment of coronary allograft vasculopathy: a reviewSachin Logani
Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
J Interv Cardiol 24:9-14. 2011..After reviewing the relevant published literature, it is our recommendation that the use of IVUS be considered in all post-transplant CAV screening...
- Ethical considerations for ventricular assist device support: a 10-point modelRalph J Petrucci
Department of Psychiatry, Drexel University College of Medicine Hahnemann University Hospital, Philadelphia, Pennsylvania 19102, USA
ASAIO J 57:268-73. 2011..This three-phase 10-point model addresses the ethical and psychosocial issues that should be discussed with patients undergoing VAD support...
- Hypertension in heart transplant recipients: more than just cyclosporineHoward J Eisen
J Am Coll Cardiol 41:433-4. 2003
- Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejectionMandeep R Mehra
Division of Cardiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
J Heart Lung Transplant 27:297-301. 2008..We have previously demonstrated that a peripheral blood transcriptional profile using 11 distinct genes predicts onset of cardiac allograft rejection weeks to months prior to the actual event...
- Transcriptional signals of T-cell and corticosteroid-sensitive genes are associated with future acute cellular rejection in cardiac allograftsMandeep R Mehra
Division of Cardiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
J Heart Lung Transplant 26:1255-63. 2007..Profiling mRNA levels of 11 informative genes expressed by circulating immune effector cells identifies cardiac allograft recipients at low risk for current moderate-severe acute cellular rejection (ACR)...
- Adverse outcomes from the use of older donor hearts in cardiac transplant recipients: the pros and cons of expanded donor criteriaHoward J Eisen
J Am Coll Cardiol 43:1562-4. 2004
- Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysisMario Vigano
Department of Cardiac Surgery, San Matteo Hospital, Pavia, Italy
J Heart Lung Transplant 26:584-92. 2007..Everolimus is an immunosuppressive agent that reduces cardiac allograft vasculopathy. This report presents the 24-month results of a multicenter trial of everolimus vs azathioprine in heart transplantation...
- Daclizumab to prevent rejection after cardiac transplantationRay E Hershberger
Department of Medicine Cardiology, UHN 62, Oregon Health and Science University, Portland, OR 97239, USA
N Engl J Med 352:2705-13. 2005..We conducted a multicenter, placebo-controlled, double-blind study to confirm these results in cardiac-transplant patients...
- The economic implications of noninvasive molecular testing for cardiac allograft rejectionRoger W Evans
Am J Transplant 5:1553-8. 2005....
- Statin use and risks of death or fatal rejection in the Heart Transplant Lipid RegistryAudrey H Wu
Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA
Am J Cardiol 95:367-72. 2005..Statin therapy was significantly associated with lower risk of death and fatal rejection, benefits that were independent of lipid values...
- Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter studyJon A Kobashigawa
Department of Cardiology, University of California at Los Angeles, Los Angeles, California 90095, USA
J Heart Lung Transplant 25:935-41. 2006..Enteric-coated mycophenolate sodium (EC-MPS, myfortic) is an advanced formulation that delays the release of mycophenolic acid (MPA). Its efficacy and safety has been proven in several clinical trials in renal transplantation...
- Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study)Michael Phillips
Menssana Research, Inc Fort Lee, New Jersey, USA
J Heart Lung Transplant 23:701-8. 2004..Rejection is accompanied by oxidative stress that degrades membrane polyunsaturated fatty acids, evolving alkanes and methylalkanes, which are excreted in the breath as volatile organic compounds (VOCs)...
- Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-upNabil Dib
Arizona Heart Institute, Phoenix, AZ 85006, USA
Circulation 112:1748-55. 2005..In addition, we sought to gain preliminary information on graft survival and any associated changes in cardiac function...
- Exercise training and myocardial energetics in patients with heart failure: when more is lessHoward J Eisen
J Am Coll Cardiol 51:1892-5. 2008
- Prediction of heart transplant rejection with a breath test for markers of oxidative stressMichael Phillips
Menssana Research Inc, Fort Lee, New Jersey, USA
Am J Cardiol 94:1593-4. 2004..98, and 100% specific when the p value was </=0.058; in the intermediate group, the breath test determined the probability of grade 3 rejection and the predictive value of the result...
- Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathyNabil Dib
Arizona Heart Institute, 2632 N 20th Street, Phoenix, AZ 85006, USA
Cell Transplant 14:11-9. 2005..These interim results demonstrate survival, feasibility, and safety of autologous myoblast transplantation and suggest that this modality may offer a potential therapeutic treatment for end-stage heart disease...